🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSURMOUNT-MMO: tirzepatide for morbid obesity — anyone have experience? Page 3

SURMOUNT-MMO: tirzepatide for morbid obesity — anyone have experience?

jason_paloalto Wed, Feb 18, 2026 at 8:14 AM 22 replies 986 viewsPage 3 of 5
DadBodDave
Member
187
923
Nov 2024
Ohio
Feb 18, 2026 at 5:45 PM#11
NurseAsh_DET said:
SURMOUNT-1 landed around 20.9% mean weight loss at 15mg over 72 weeks, against roughly 15% for semaglutide 2.4mg in STEP 1.

Genuinely useful, thank you. I had the facts and not the framework. Printing the relevant bit and taking it with me.

16 14laura_annarbor, JenMemphis, pat_auckland and 13 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Feb 18, 2026 at 9:30 PM#12

Clinical perspective, offered as context rather than as advice. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

17 15anna.melb_AU, mark_tokyo, hans_munich and 14 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Feb 19, 2026 at 1:15 AM#13
PedsEndoPhilly said:
The mechanism and the magnitude are separate questions.

Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.

Ask again with the specifics and you will get a better answer than this one.

18 16SteveThurs, B12Beth, RickReta_CO and 15 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Feb 19, 2026 at 5:00 AM#14

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

19 17amsterdam_pete, LondonLisa, mike_nyc and 16 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Feb 19, 2026 at 8:45 AM#15

Moderator note: a couple of off-topic posts removed. Report rather than reply if it drifts again.

20 18PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 17 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register